GeoVax to Present COVID-19 Vaccine Data for Immunocompromised Patients at World Vaccine Congress Europe 2025

GeoVax Labs, Inc., a clinical-stage biotechnology company, announced that members of its executive medical and scientific team will deliver presentations at the upcoming World Vaccine Congress Europe 2025, scheduled for October 13–16, 2025, at the RAI Amsterdam Convention Centre. Mark J. Newman, PhD, GeoVax Chief Scientific Officer, will participate in the Special Populations Workshop during the Pre-Congress Workshops on Monday, October 13. His presentation, titled "Vaccine design to address the immunocompromised: T-lymphocyte driven…Balanced immunity - Broader specificity - Increased memory," will focus on challenges in vaccine development for vulnerable populations, including the immunocompromised.

Kelly T. McKee, Jr., MD, MPH, GeoVax Chief Medical Officer, will present a scientific poster titled "Interim Safety and Reactogenicity of GEO-CM04S1, an MVA-vectored, multi-antigen COVID-19 vaccine, in adults with hematologic malignancies receiving cellular therapies." The poster, highlighting the safety profile of the GEO-CM04S1 COVID-19 vaccine in an important target population, will be on display in the Poster Zone, Exhibition Hall from October 14–16. David Dodd, GeoVax President & CEO, emphasized the significance of the event, stating, "World Vaccine Congress Europe is one of the most important international gatherings in vaccine research, development and policy. We look forward to highlighting the progress of our multi-antigen GEO-CM04S1 in immunocompromised populations, where the need for more effective vaccine options remains urgent."

The World Vaccine Congress Europe convenes global experts across science, clinical development, manufacturing, and public health. More details can be found at https://www.terrapinn.com/conference/world-vaccine-congress-europe. GeoVax's lead clinical program, GEO-CM04S1, is a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials. It is being evaluated as a primary vaccine for immunocompromised patients, such as those with hematologic cancers, and as a booster in patients with chronic lymphocytic leukemia and healthy individuals who previously received mRNA vaccines. For more information about the current status of clinical trials and other updates, visit https://www.geovax.com.